Compare McKesson Corporation (MCK) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Direxion Daily TSLA Bull 2X Shares — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Direxion Daily TSLA Bull 2X Shares trades at $11.24. The key difference: McKesson Corporation pays a 0.39% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and McKesson Corporation is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| MCK | TSLL | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $23.03 |
52-Week Low | $659.01 | $10.29 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
TSLL is trading at $10.72, down 5.84% with a bearish technical outlook. The stock faces selling pressure with moving averages indicating a downtrend and key resistance at $12. Recent news highlights upcoming Tesla earnings as a potential catalyst, though financial ratios remain unavailable for fundamental assessment.
The stock's outlook is cautious due to technical weakness and lack of current financial data. Investment opportunity hinges on Tesla's upcoming earnings report, while risks include sustained bearish momentum and dependency on Tesla's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
